Manuscript Submission. Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations and Homologous Recombination Deficiency (HRD) Abstract Sonu Kumar Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represe... See more
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder characterized by progressive motor and non-motor symptoms, dopaminergic neuronal loss, and pathological α-synuclein aggregation (Kalia & Lang, 2015; Poewe et al., 2017).Despite su... See more
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) represent a paradigm shift in precision oncology, exploiting synthetic lethality to selectively target tumor cells deficient in homologous recombination repair (HRR) pathways, particularly those harbor... See more
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, α-synuclein aggregation, and disrupted motor and non-motor function (Bloem et al., 2021). Pharmacological replenishment of dopamine using L-3... See more
